Trial Profile
An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleeding
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2022
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Hereditary haemorrhagic telangiectasia
- Focus Therapeutic Use
- Acronyms ROW
- 10 Aug 2022 Status changed from recruiting to completed.
- 26 Jul 2016 New trial record